Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

Truist Securities analyst Gregory Renza has maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN) and raised the price target from $772 to $780. This adjustment reflects a positive outlook for the company's performance in the market.